Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial.
Geurts VCM, Voorwerk L, Balduzzi S, Salgado R, Van de Vijver K, van Dongen MGJ, Kemper I, Mandjes IAM, Heuver M, Sparreboom W, Haanen JBAG, Sonke GS, Horlings HM, Kok M. Geurts VCM, et al. Among authors: van dongen mgj. Breast. 2023 Aug;70:76-81. doi: 10.1016/j.breast.2023.06.007. Epub 2023 Jun 27. Breast. 2023. PMID: 37393645 Free PMC article. Clinical Trial.
Allele-specific regulation of FGFR2 expression is cell type-dependent and may increase breast cancer risk through a paracrine stimulus involving FGF10.
Huijts PE, van Dongen M, de Goeij MC, van Moolenbroek AJ, Blanken F, Vreeswijk MP, de Kruijf EM, Mesker WE, van Zwet EW, Tollenaar RA, Smit VT, van Asperen CJ, Devilee P. Huijts PE, et al. Breast Cancer Res. 2011 Jul 18;13(4):R72. doi: 10.1186/bcr2917. Breast Cancer Res. 2011. PMID: 21767389 Free PMC article.
PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.
Voorwerk L, Isaeva OI, Horlings HM, Balduzzi S, Chelushkin M, Bakker NAM, Champanhet E, Garner H, Sikorska K, Loo CE, Kemper I, Mandjes IAM, de Maaker M, van Geel JJL, Boers J, de Boer M, Salgado R, van Dongen MGJ, Sonke GS, de Visser KE, Schumacher TN, Blank CU, Wessels LFA, Jager A, Tjan-Heijnen VCG, Schröder CP, Linn SC, Kok M. Voorwerk L, et al. Among authors: van dongen mgj. Nat Cancer. 2023 Apr;4(4):535-549. doi: 10.1038/s43018-023-00542-x. Epub 2023 Apr 10. Nat Cancer. 2023. PMID: 37038006 Free PMC article. Clinical Trial.
Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study.
Shapira-Frommer R, Mileshkin L, Manzyuk L, Penel N, Burge M, Piha-Paul SA, Girda E, Lopez Martin JA, van Dongen MGJ, Italiano A, Xu L, Jin F, Norwood K, Ott PA. Shapira-Frommer R, et al. Among authors: van dongen mgj. Gynecol Oncol. 2022 Aug;166(2):211-218. doi: 10.1016/j.ygyno.2022.01.029. Epub 2022 Mar 28. Gynecol Oncol. 2022. PMID: 35361487 Free article. Clinical Trial.
Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.
Marabelle A, Cassier PA, Fakih M, Kao S, Nielsen D, Italiano A, Guren TK, van Dongen MGJ, Spencer K, Bariani GM, Ascierto PA, Santoro A, Shah M, Asselah J, Iqbal S, Takahashi S, Piha-Paul SA, Ott PA, Chatterjee A, Jin F, Norwood K, Delord JP. Marabelle A, et al. Among authors: van dongen mgj. Lancet Gastroenterol Hepatol. 2022 May;7(5):446-454. doi: 10.1016/S2468-1253(21)00382-4. Epub 2022 Feb 1. Lancet Gastroenterol Hepatol. 2022. PMID: 35114169 Clinical Trial.
Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer.
Molenaar-Kuijsten L, Braal CL, Groenland SL, de Vries N, Rosing H, Beijnen JH, Koolen SLW, Vulink AJE, van Dongen MGJ, Mathijssen RHJ, Huitema ADR, Steeghs N; Dutch Pharmacology Oncology Group (DPOG). Molenaar-Kuijsten L, et al. Among authors: van dongen mgj. Clin Pharmacol Ther. 2022 Feb;111(2):477-484. doi: 10.1002/cpt.2455. Epub 2021 Nov 6. Clin Pharmacol Ther. 2022. PMID: 34674222 Clinical Trial.
Mathematical modeling of the glucagon challenge test.
Masroor S, van Dongen MGJ, Alvarez-Jimenez R, Burggraaf K, Peletier LA, Peletier MA. Masroor S, et al. Among authors: van dongen mgj. J Pharmacokinet Pharmacodyn. 2019 Dec;46(6):553-564. doi: 10.1007/s10928-019-09655-2. Epub 2019 Sep 30. J Pharmacokinet Pharmacodyn. 2019. PMID: 31571122 Free PMC article.
15 results